Category Archives: Glucagon and Related Receptors

Supplementary MaterialsFigure 1

Supplementary MaterialsFigure 1. disease control prices (DCR, 8.3% vs. 40.2%), shorter median progression-free survival (PFS; 1.9 vs. 5.3 months), and shorter median overall survival (OS; 10.4 vs. 17.9 months). For patients treated with immune checkpoint inhibitors (= 31), activating Rutaecarpine … Continue reading

Posted in Glucagon and Related Receptors | Comments Off on Supplementary MaterialsFigure 1